Shy S. Baranov joined our firm as a partner in 2021.
With over 23 years of legal experience, including as a Managing Partner and Head of the Commercial Department at ZAG law, Shy has gained extensive experience in the fields of corporate and commercial law. Over the years Shy has accompanied numerous companies in their local and international transactions.
Shy has extensive experience in advising and representing Israeli companies from across many sectors, in relation to their operations internationally in general and specifically in the U.S.
Shy has a deep understanding of practical experience and knowledge of U.S. law in general, and U.S. securities law in particular, and uses this experience in serving as Israeli counsel on a wide range of financing transactions in the U.S., including initial public offerings (IPOs), follow-on offerings, ATMs, PIPEs and other kinds of financing transactions.
Shy has unique expertise in representing Israeli companies that are traded overseas. In this respect, he counsels regularly on international public M&A transactions, corporate governance matters, shareholders activism, crisis management and interested party transactions.
Representative Client Work
Equity Offerings and Public Listings:
• Represented Radcom Ltd. (Nasdaq: RDCM) as U.S. and Israeli counsel in its two follow-on public offering of ordinary shares raising an aggregate amount of more than $55M.
• Represented Alcobra Ltd. (formerly Nasdaq: ADHD) as U.S. and Israeli counsel in its Initial Public Offering and three follow on public offerings raising an aggregate amount of $134M.
• Represented Bioblast Pharma, Ltd. (formerly Nasdaq: ORPN) as U.S. and Israeli counsel in its Initial Public Offering and a follow on public offering raising an aggregate approximate amount of $42M.
• Represented BiomX Ltd. in its $24M Series Preferred A and $32M Series Preferred B financings.
• Represented Syqe Medical Ltd. in its $30M Series Preferred A financing.
Mergers and Acquisitions:
• Represents BiomX Ltd. as Israeli counsel in its $254M merger with Chardan Healthcare Acquisition corp. a special purpose acquisition company and related investment of $60M.
• Represents Pointer Telocation Ltd. (Nasdaq, TASE: PNTR) as U.S. and Israeli counsel in its sale valued at $140M in cash and stock.
• Represented Alcobra Ltd. (formerly Nasdaq: ADHD) as U.S. and Israeli counsel in its reverse IPO merger with Arcturus Therapeutics Inc. (“Arcturus”) at a transaction valued at $117M.
• Represented Alcobra Ltd. (formerly Nasdaq: ADHD) as U.S. and Israeli counsel in an asset purchase agreement for the sale of its Abuse-Deterrent Amphetamine Immediate-Release (ADAIR) development assets to an investor group. The agreement was signed simultaneously with the closing of the merger between Alcobra and Arcturus mentioned above.
• Represented Bioblast Pharma Ltd. (formerly Nasdaq: ORPN) as U.S. and Israeli counsel in its reverse IPO merger with Enlivex Therapeutics Ltd., at a transaction valued at $117M.
• Represented Bioblast Pharma Ltd. (formerly Nasdaq: ORPN) as U.S. and Israeli counsel in an Asset Purchase Agreement with Seelos Therapeutics, Inc. in consideration of royalties and $20M guaranteed and milestones-based cash consideration.
